Matrixx Rejected On ProPhase Labs Bid, Picks Up Option On Shares
This article was originally published in The Tan Sheet
Executive Summary
In a bid to dominate the market for zinc cold remedies, Matrixx Initiatives attempts to acquire ProPhase Labs, but is turned away by CEO Ted Karkus who asserts ProPhase’s growth prospects outweigh the benefits of a sale.